The latest market report published by Acute Market Reports “Global Chronic Myelogenous Leukemia (CML) Treatment Market – Growth, Share, Opportunities, Competitive Analysis and Forecast, 2019-2029 âThe Chronic Myelogenous Leukemia (CML) Treatment market was valued at USD 2.8 billion in 2019 and is expected to grow at a CAGR of 4% by 2021 to 2029.
Browse the full Chronic Myelogenous Leukemia (CML) Market Report – Growth, Share, Opportunities, Competitive Analysis and Forecast, 2019-2029 at https://www.acutemarketreports.com/report/chronic-myeloid-leukemia-cml-treatment-market
According to the Leukemia Foundation, chronic myelogenous leukemia (CML) is a type of cancer that affects the some blood and bone marrow. In CML, the bone marrow creates too many white blood cells or granulocytes which gradually invade the bone marrow, interfering with the production of blood cells. This bone marrow spreads and is allowed to circulate in the bloodstream. This leads to easy bruising, bleeding and anemia, as there is a shortage of red blood cells and platelets.
The number of people diagnosed with CML worldwide is expected to reach 144,000 by 2030. There has been a significant advance in the treatment regimen for CML over the past two decades. There has been a significant increase in the number of new drugs approved for the treatment of CML. The new class of drugs that have transformed treatment for CML include tyrosine kinases (TKIs) or BCR-ABL inhibitors. They are a crucial component in the treatment of CML. First generation imatinib and the more effective second generation BCR-ABL inhibitor, nilotinib and dasatinib, along with ponatinib and bosutinib have been approved for marketing. Some studies have shown that nilotinib and dasantinib are more effective than animatinib in first-line chronic phase CML. This offered better results and a better and faster response.
North America has been considered the largest treatment for CML due to factors such as the increased rate of diagnosis in cancer patients, the growing awareness of CML patients to new drug treatments, and the increased awareness of CML patients. highest annual treatment price compared to other regions. According to Cancer.net, about 10% of all leukemias are from CML. In 2019, approximately 8,220 people (4,610 men and 3,610 women) in the United States were diagnosed with CML. Most were adults, with an average age of diagnosis of 64 years. It is estimated that 1,070 deaths (570 men and 500 women) have occurred this year. The American Cancer Society estimates that in 2016, about 8,220 new cases will be diagnosed with CML (4,610 in men and 3,610 in women) and that about 1,070 people will die from CML (570 men and 500 women). Thus, North America is expected to retain its dominance in the near future.
North America was the market leader for CML treatment in 2019. The main determinants were strong awareness leading to early diagnosis, a well-developed healthcare setup and a supportive reimbursement scenario, approval. rapid drug delivery and accessibility to new targeted drug therapies. Of a total of 8,450 patients diagnosed in 2019, 4,970 were men and 3,480 were women. Of 1,130 deaths in 2020, 670 were men and 460 were women. The treatment regimen for CML has evolved considerably over the past decade. For example, in 2012, the USFDA approved 3 drugs, including bosutinib, ponatinib, and stomachetaxine. Likewise, in 2013, three other key drugs were approved, namely ponatinib, stomachetaxine and bosutinib. The main challenge in receiving treatment is affordability of drugs. The prices are considerably high and this limits the accessibility of expensive drugs in developing economies. Therefore, it limits the growth of CML treatment. However, with new drug approvals and government initiatives to make treatment affordable, the emergence of crowdfunding for treatment is expected to drive the market growth during the forecast period of 2021 to 2029. Key companies on this market are Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., Pfizer, Inc., Hospira, Inc., Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Stragen Pharma SA, Otsuka Pharmaceutical Co ., Ltd. and others.
Main market movements:
- Targeted therapy contributed the most to CML treatment market revenue in 2019. The main driver included increasing the level of effectiveness with new drug options, support from the insurance framework, increased awareness of patients with early diagnosis and targeted therapy.
- North America was the market leader for CML treatment in 2019. The main determinants were strong awareness leading to early diagnosis, a well-developed healthcare setup and a supportive reimbursement scenario, approval. rapid drug delivery and accessibility to new targeted drug therapies.
- Imatinib is effective, but second and third generation therapies are recommended for patients. Imatinib remains ineffective.
Acute market reports is a global market research and consulting firm that serves driving organizations, governments, non-legislative associations, and non-profit organizations. We provide assistance to our clients to make lasting improvements to their execution and understand their most pressing goals.